Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
- 21 October 2009
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 119 (2) , 379-390
- https://doi.org/10.1007/s10549-009-0575-y
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- PIK3CA Mutation Associates with Improved Outcome in Breast CancerClinical Cancer Research, 2009
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast CancerCancer Research, 2008
- Targeting phosphoinositide 3-kinase—Moving towards therapyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2008
- Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast CarcinomasClinical Cancer Research, 2007
- PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast CancerClinical Cancer Research, 2007
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- Estrogen-Independent Proliferation Is Present in Estrogen-ReceptorHER2-Positive Primary Breast Cancer After Neoadjuvant LetrozoleJournal of Clinical Oncology, 2006
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001